This is an international site for KISQALI® (ribociclib)
and is intended for healthcare professionals outside the US.
This is an international site for KISQALI® (ribociclib)
and is intended for healthcare professionals outside the US.
The information on this site is not country-specific and may contain details that are outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
Visit your local HCP portal for further country specific information
This website is intended for Health Care Professionals (HCPs) outside the US, and Switzerland, and UK. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information. By clicking continue you are confirming that you are an HCP.
For Healthcare
Professionnals
Outside the US
KISQALI is proven in patients with HR+/HER2 - early and advanced breast cancer (EBC and ABC).
To find out more, start by choosing an indication.